One design doesn’t fit all: The short journey to a successful bispecific therapeutic antibody

Transitioning from single-functional antibodies to sophisticated bispecific designs not only introduces unique challenges for drug developers but also demands innovative approaches. Unlike traditional antibodies, bispecifics require carefully tailored screening strategies in order to identify the most effective format to move forward into development.

Join us on Oct. 14^th for a complimentary lunch seminar focused on design strategies and considerations for bispecific antibodies. Hear from our Sr. Manager of Protein Engineering, Dr Thomas Cornell, as he shares valuable insights into the methodologies that can help you successfully navigate the complexities of bispecific antibody development.

Using case studies, Dr Cornell will thoroughly explore the principles and practices of developing successful bispecific antibodies and discuss Abzena’s unique approach that’s been proven to accelerate and de-risk their development path to IND. Our systematic approach aims to streamline the screening process, allowing for broad exploration while maintaining minimal designs.  Specifically, he will delve into intelligent bispecific design, focusing on key factors such as avidity, spacing, and the formatting of fragment antigen binding (Fab) and single-chain fragment vehicle (scFv) arms.

You will learn:

• Key Design Considerations for Bispecific Candidates: Discover what elements to include and avoid in order to optimize your designs
• Efficiently Improving Purity with Single-Step Purification: Uncover methods to enhance antibody purity efficiently
• In-Depth Case Study on Screening Strategies: Gain an understanding of the importance of screening multiple designs through a detailed case study

Event Details:

• Date: October 14
•  Event Timeline:
  • 11:30am to 12:00pm – Guests check-in
  • 12:00pm to 13:00pm – Lunch and presentation
  • 13:00pm to 13:30pm – Q&A and dessert
• Location: Radisson Blu Hotel Basel in the Oslo meeting room
• Hotel Website:  Hotel in Basel Near Train Station – Book Now | Radisson Blu (radissonhotels.com)

Register Here

Speaker details:

Dr Thomas Cornell, Sr. Manager of Protein Engineering

Thomas Cornell gained his Ph.D. from Kings College London in the field of Chemical Biology. He then moved into the biotech startup space and spent almost a decade in preclinical vaccine research and development, focused on subunit vaccines. After working on over 20 protein families, Tom has gained a wealth of protein engineering experience. Tom joined Abzena 2 years ago and works within the protein engineering department working on pre-clinical development of Antibody drug candidates.

Register Here